(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.47%) $79.32
(-0.34%) $2.03
(0.15%) $2 313.00
(0.38%) $26.93
(0.36%) $966.10
(-0.08%) $0.932
(-0.19%) $10.97
(-0.09%) $0.797
(-0.02%) $91.11
0.23% ¥ 1 714.00
Live Chart Being Loaded With Signals
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally...
Stats | |
---|---|
Šios dienos apimtis | 15 400.00 |
Vidutinė apimtis | 0.00 |
Rinkos kapitalizacija | 0.00 |
Last Dividend | ¥20.00 ( 2022-09-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 0.0000163 |
ATR14 | ¥0 (0.00%) |
Nissui Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Nissui Pharmaceutical Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥16.66B |
Bruto pelnas: | ¥5.26B (31.57 %) |
EPS: | ¥127 333 333 |
FY | 2022 |
Pajamos: | ¥16.66B |
Bruto pelnas: | ¥5.26B (31.57 %) |
EPS: | ¥127 333 333 |
FY | 2021 |
Pajamos: | ¥12.38B |
Bruto pelnas: | ¥4.20B (33.90 %) |
EPS: | ¥71 190 746 |
FY | 2020 |
Pajamos: | ¥12.77B |
Bruto pelnas: | ¥5.73B (44.83 %) |
EPS: | ¥44 054 372 |
Financial Reports:
No articles found.
Nissui Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2001-03-27 |
Last Dividend | ¥20.00 | 2022-09-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 38 | -- |
Total Paid Out | ¥454.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.24 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 1.462 | |
Div. Directional Score | 6.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8093.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
7427.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
6643.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5975.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4668.T | Ex Dividend Junior | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
3912.T | Ex Dividend Junior | 2023-12-28 | Sporadic | 0 | 0.00% | |
3141.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
2060.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
9003.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
8558.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0688 | 1.500 | 8.62 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0310 | 1.200 | 8.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0352 | 1.500 | -0.720 | -1.080 | [0.1 - 1] |
payoutRatioTTM | 0.875 | -1.000 | 1.248 | -1.248 | [0 - 1] |
currentRatioTTM | 8.29 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.255 | 0.800 | 7.32 | 5.86 | [0.8 - 2.5] |
cashRatioTTM | 1.248 | 1.500 | 4.18 | 6.27 | [0.2 - 2] |
debtRatioTTM | 0.00306 | -1.500 | 9.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 24.23 | 1.000 | 2.14 | 2.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 111 778 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 100 889 000 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00347 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.316 | 1.000 | 8.07 | 8.07 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.103 | 1.000 | 9.93 | 9.93 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.90 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.451 | 0.800 | -0.326 | -0.261 | [0.5 - 2] |
Total Score | 10.92 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0000135 | 1.000 | -0.101 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0352 | 2.50 | -0.463 | -1.080 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 100 889 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 111 778 000 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.875 | 1.500 | 1.248 | -1.248 | [0 - 1] |
pegRatioTTM | 0.0000002 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0604 | 1.000 | -0.990 | 0 | [0.1 - 0.5] |
Total Score | 1.462 |
Nissui Pharmaceutical
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.